- Silexion Therapeutics Corp. announced positive new human cell line data for its drug candidate **SIL204**, confirming **pan-KRAS activity** with inhibition rates ranging from **83.5% to 99.7%** across eleven human cancer cell lines from five different organ sites.  **[2022416_0001178913-25-003444_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003444_exhibit_99-1.htm:1]** 
- The data demonstrated activity against clinically significant KRAS mutations including G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D, with the **highest reported activity of 99.7% inhibition** in NCIH2009 lung cancer cells.  **[2022416_0001178913-25-003444_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003444_exhibit_99-1.htm:1]** 
- This includes the **first evidence of activity in gastric cancer** (89.2% inhibition in SNU-601 cells) and expanded validation in colorectal cancer, reinforcing SIL204's potential as a single therapeutic approach for multiple KRAS-driven solid tumors.  **[2022416_0001178913-25-003444_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003444_exhibit_99-1.htm:1]** 
- The company plans to advance SIL204 towards **Phase 2/3 clinical trials in the first half of 2026**, with regulatory submissions expected in **Q4 2025** for Israel and **Q1 2026** for the European Union.  **[2022416_0001178913-25-003444_exhibit_99-1.htm:1]**

Silexion Therapeutics announces positive preclinical data for SIL204

- **Silexion Therapeutics Corp (SLXN)** entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC on **September 26, 2025**.  **[2022416_0001178913-25-003385_zk2533809.htm:1]** **[2022416_0001178913-25-003385_exhibit_10-1.htm:0]** 
- This agreement permits SLXN to offer and sell up to **$13.17 million** of its **ordinary shares** through Wainwright as an agent.  **[2022416_0001178913-25-003385_zk2533809.htm:1]** 
- Wainwright will receive a **cash commission of 3%** of the gross sales price of any ordinary shares sold under the agreement.  **[2022416_0001178913-25-003385_zk2533809.htm:1]** **[2022416_0001178913-25-003385_exhibit_10-1.htm:4]** 
- Sales will be conducted using "at the market offering" methods, including transactions on The Nasdaq Capital Market.  **[2022416_0001178913-25-003385_zk2533809.htm:1]**

Silexion Therapeutics Corp enters At The Market Offering Agreement

- Silexion Therapeutics Corp (SLXN) has affirmed compliance with Nasdaq Listing Rule 5550(b)(1), reporting a **pro forma shareholders' equity of approximately $9.41 million** as of July 31, 2025, significantly exceeding the **$2.5 million** minimum requirement.  **[2022416_0001178913-25-003329_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003329_zk2533784.htm:2]** 
- This achievement follows a **capital deficiency of $0.7 million** as of July 31, 2025, and **$0.1 million** in shareholders' equity as of June 30, 2025.  **[2022416_0001178913-25-003329_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003329_zk2533784.htm:2]** 
- The increase in equity resulted from four significant transactions completed in August and September 2025, including an induced warrant exercise, a public offering, the exercise of Series B ordinary warrants, and the partial conversion of a sponsor promissory note, which collectively added **$10.31 million** to shareholders' equity.  **[2022416_0001178913-25-003329_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003329_zk2533784.htm:2]** **[2022416_0001178913-25-003329_zk2533784.htm:3]** **[2022416_0001178913-25-003329_zk2533784.htm:4]**

Silexion Therapeutics Corp Affirms Nasdaq Equity Compliance

- **Silexion Therapeutics Corp.** announced the **pricing of a public offering** of **1,500,000 ordinary shares** (or ordinary share equivalents) and accompanying warrants at a combined public offering price of **$4.00 per share** (or per ordinary share equivalent).  **[2022416_0001178913-25-003309_exhibit_99-1.htm:0]** 
- The offering is expected to generate **gross proceeds of $6.0 million** and **net proceeds of approximately $5.2 million**.  **[2022416_0001178913-25-003309_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003309_zk2533780.htm:2]** 
- The company intends to use the net proceeds from this offering to **advance its pre-clinical studies** and for **general corporate purposes**.  **[2022416_0001178913-25-003309_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003309_zk2533780.htm:2]** 
- The offering includes Series A warrants exercisable for five years and Series B warrants exercisable for twelve months, both with an exercise price of **$4.00 per share**, as well as pre-funded warrants with an exercise price of **$0.0001 per share**.  **[2022416_0001178913-25-003309_exhibit_99-1.htm:0]** **[2022416_0001178913-25-003309_zk2533780.htm:1]**

Silexion Therapeutics Announces Pricing of Public Offering

- Silexion Therapeutics Corp. announced **positive preclinical data** for its RNA interference (RNAi) therapy, SIL204, demonstrating its ability to successfully reach and show anti-tumor activity in major pancreatic cancer metastatic sites (liver, peritoneum, and lung) following systemic administration.  **[2022416_0001178913-25-003292_exhibit_99-1.htm:0]** 
- The study, which used human equivalent dosing, observed **measurable reductions in tumor burden** across multiple organs, with statistically significant reductions (p<0.01) achieved in the peritoneum, lung, and intestine.  **[2022416_0001178913-25-003292_exhibit_99-1.htm:0]** 
- The company remains on track to initiate **Phase 2/3 clinical trials** evaluating its dual-route administration approach in **H1 2026**, following planned regulatory submissions in **Q4 2025** and **Q1 2026**.  **[2022416_0001178913-25-003292_exhibit_99-1.htm:0]**

Silexion Therapeutics Reports Positive Preclinical Data for SIL204

- Silexion Therapeutics Corp published an updated corporate presentation on **September 2, 2025**, which will be presented at the H.C. Wainwright Global Investment Conference from **September 8-10, 2025**.  **[2022416_0001178913-25-003205_zk2533739.htm:1]** 
- The company completed a **Phase 2 proof-of-concept clinical trial** for its first-generation product, **siG12DLoder siRNA**, in locally advanced pancreatic cancer, demonstrating a **9.3 months improvement in overall survival**.  **[2022416_0001178913-25-003205_exhibit_99-1.htm:1]** **[2022416_0001178913-25-003205_exhibit_99-1.htm:7]** 
- Silexion is advancing **SIL204**, a second-generation pan-KRAS mutation silencing siRNA, with a **Phase 2/3 clinical trial** planned for **Q2 2026**.  **[2022416_0001178913-25-003205_exhibit_99-1.htm:1]** **[2022416_0001178913-25-003205_exhibit_99-1.htm:7]** 
- **GMP-grade SIL204** is anticipated to be ready for the Phase 2/3 clinical trial by **Q1 2026**, supported by **strong intellectual property protection** extending until at least **2043**.  **[2022416_0001178913-25-003205_exhibit_99-1.htm:1]** **[2022416_0001178913-25-003205_exhibit_99-1.htm:6]**

Silexion Therapeutics (SLXN)